Combining IL-17A neutralization with immune checkpoint inhibitors (ICIs) has been shown to not only maintain the anti-tumor efficacy of ICIs but also to inhibit PD-L1 expression in breast cancer cells (210). The gene discussed is IL17A; the disease is breast carcinoma.